President of the Audit committee, Chief Executive Officer of Stallergenes
Christian Chavy brings substantial pharma and biotech management experience to the Board. He is currently Chief Executive Officer of Stallergenes. In 2010, Mr. Chavy joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals. Prior to joining Actelion, he was Vice President at Serono’s reproductive medicine strategic unit in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.
Richard Pasternak, M.D.
Member of the Audit committee, Chairman
Dr. Pasternak has had a long-standing research interest in lipid disorders and atherosclerosis, as well as patterns of practice and disease management and prevention. Previously, he was Vice President, Head of Cardiovascular Clinical Research and Head of Global Scientific Affairs and Scientific Leadership at Merck & Co from 2004 and 2010. Prior to this, he was Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital from 1992 to 2004, and he was Associate Professor of Medicine at the Harvard Medical School.
Dr. Pasternak has authored more than 100 publications and has spoken widely on the development of drugs for the treatment of cardiovascular diseases, and about how academia and industry can better collaborate in biomedical research. He is currently a faculty member of the Weill Cornell School of Medicine, and serves on the Boards of the Founder’s Affiliate of the American Heart Association, the Galien Foundation, and Essentialis Therapeutics.
Catherine Moukheibir, MA, MBA
Member of the Audit committee, Professional board director
Catherine Moukheidir has 23 years of experience in finance including 18 in the biotechnology industry, holding multiple leadership roles and Board roles. She is chairman of MedDay Pharmaceuticals (private, France), chairman of the audit committee and independent board member of Zealand (public, Denmark), chairman of the audit committee and independent board member of Genkyotex (public, France), independent board member and member of the audit committee of Ablynx (public, Belgium) and Cerenis Therapeutics (public, France). Between March 2011 and December 2016, she was a member of the Executive Board of Innate Pharma (public, France) where she was responsible for a major financial restructuring.